CTOs on the Move

Raland Technologies

www.raland.com

 
Raland Technologies is a Fairport, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.raland.com
  • 1387 Fairport Rd
    Fairport, NY USA 14450
  • Phone: 877.972.5263

Executives

Name Title Contact Details

Similar Companies

USA Rapid Test

COVID Tests, Rapid Test, Protocols, Atmofizer, Air Purification, Antigen Test, Antibody Test, My Protect Kit, Coronavirus Detection, David Lee Jensen, Tampa FL

Southeast Orthopedic Specialists

Our team of orthopedic surgeons and physical therapists serve Jacksonville, Orange Park and St. Augustine. We offer expert care for bones, muscles, and joints. Call (904) 634-0640 for an appointment!

Newlink Genetics

NewLink Genetics is a biopharmaceutical company focused on discovering, developing, and commercializing novel immuno-oncology product candidates to improve the lives of patients with cancer. Founded more than 15 years ago, NewLink Genetics continues to be at the forefront in immuno-oncology treatments led by a diverse group of industry professionals and physician-scientists. Personal cancer stories inspire our relentless research and development in advancing treatments. Our grand passion is to change the cancer treatment paradigm and make a difference in patient lives every day.

Eledon

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for people undergoing organ or cellular transplantation, and for people with autoimmune and neurodegenerative disease. Our lead program, AT-1501, is a potential best-in-class humanized IgG1 anti-CD40L antibody with high affinity for CD40L, a well-validated biological target with broad therapeutic potential. The CD40/CD40L pathway plays a central role in generating pro-inflammatory responses in autoimmune disease, allograft transplant rejection, and neuroinflammation.

Trevi Therapeutics

Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.